Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease
This study is enrolling participants by invitation only.
Sponsor:
Dynavax Technologies Corporation
Information provided by:
Dynavax Technologies Corporation
ClinicalTrials.gov Identifier:
NCT01282762
First received: January 20, 2011
Last updated: January 21, 2011
Last verified: January 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is enrolling participants by invitation only. |
|---|---|
| Estimated Study Completion Date: | January 2016 |
| Estimated Primary Completion Date: | January 2016 (Final data collection date for primary outcome measure) |